These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 12713066)

  • 1. Predictive factors and selection of thymidine analogue mutations by nucleoside reverse transcriptase inhibitors according to initial regimen received.
    Flandre P; Descamps D; Joly V; Meiffrédy V; Tamalet C; Izopet J; Aboulker JP; Brun-Vézinet F
    Antivir Ther; 2003 Feb; 8(1):65-72. PubMed ID: 12713066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The contribution of HIV fitness to the evolution pattern of reverse transcriptase inhibitor resistance.
    Paintsil E; Margolis A; Collins JA; Alexander L
    J Med Virol; 2006 Apr; 78(4):425-30. PubMed ID: 16482556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The L74V mutation in human immunodeficiency virus type 1 reverse transcriptase counteracts enhanced excision of zidovudine monophosphate associated with thymidine analog resistance mutations.
    Miranda LR; Götte M; Liang F; Kuritzkes DR
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2648-56. PubMed ID: 15980332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapy.
    Cozzi-Lepri A; Ruiz L; Loveday C; Phillips AN; Clotet B; Reiss P; Ledergerber B; Holkmann C; Staszewski S; Lundgren JD;
    Antivir Ther; 2005; 10(7):791-802. PubMed ID: 16312176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The reverse transcriptase 67N 70R 215Y genotype is the predominant TAM pathway associated with virologic failure among HIV type 1C-infected adults treated with ZDV/ddI-containing HAART in southern Africa.
    Novitsky V; Wester CW; DeGruttola V; Bussmann H; Gaseitsiwe S; Thomas A; Moyo S; Musonda R; Van Widenfelt E; Marlink RG; Essex M
    AIDS Res Hum Retroviruses; 2007 Jul; 23(7):868-78. PubMed ID: 17678469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure.
    Marcelin AG; Delaugerre C; Wirden M; Viegas P; Simon A; Katlama C; Calvez V
    J Med Virol; 2004 Jan; 72(1):162-5. PubMed ID: 14635026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain.
    Gómez-Cano M; Rubio A; Puig T; Pérez-Olmeda M; Ruiz L; Soriano V; Pineda JA; Zamora L; Xaus N; Clotet B; Leal M
    AIDS; 1998 Jun; 12(9):1015-20. PubMed ID: 9662197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.
    Miller V; Larder BA
    Antivir Ther; 2001; 6 Suppl 3():25-44. PubMed ID: 11678471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased multinucleoside drug resistance and decreased replicative capacity of a human immunodeficiency virus type 1 variant with an 8-amino-Acid insert in the reverse transcriptase.
    van der Hoek L; Back N; Jebbink MF; de Ronde A; Bakker M; Jurriaans S; Reiss P; Parkin N; Berkhout B
    J Virol; 2005 Mar; 79(6):3536-43. PubMed ID: 15731248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diminished selection for thymidine-analog mutations associated with the presence of M184V in Ethiopian children infected with HIV subtype C receiving lamivudine-containing therapy.
    Averbuch D; Schapiro JM; Lanier ER; Gradstein S; Gottesman G; Kedem E; Einhorn M; Grisaru-Soen G; Ofir M; Engelhard D; Grossman Z
    Pediatr Infect Dis J; 2006 Nov; 25(11):1049-56. PubMed ID: 17072129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short communication: selection of thymidine analogue resistance mutational patterns in children infected from a common HIV type 1 subtype G source.
    Däumer M; Awerkiew S; Aragón SS; Kartashev V; Poplavskaja T; Klein R; Sichtig N; Thiele B; Lengauer T; Roomp K; Pfister H; Kaiser R
    AIDS Res Hum Retroviruses; 2010 Mar; 26(3):275-8. PubMed ID: 20334563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Tenofovir DF in rescue regimens].
    López Bernaldo de Quirós JC
    Enferm Infecc Microbiol Clin; 2008 Jun; 26 Suppl 8():25-30. PubMed ID: 19195435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons.
    Garcia-Lerma JG; Nidtha S; Blumoff K; Weinstock H; Heneine W
    Proc Natl Acad Sci U S A; 2001 Nov; 98(24):13907-12. PubMed ID: 11698656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term foscarnet therapy remodels thymidine analogue mutations and alters resistance to zidovudine and lamivudine in HIV-1.
    Mathiesen S; Dam E; Roge B; Joergensen LB; Laursen AL; Gerstoft J; Clavel F
    Antivir Ther; 2007; 12(3):335-43. PubMed ID: 17591023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human immunodeficiency virus 1 strains resistant to nucleoside inhibitors of reverse transcriptase in isolates from the Czech Republic as monitored by line probe assay and nucleotide sequencing.
    Reinis M; Vandasová J; Stanková M; Linka M; Brůcková M
    Acta Virol; 2001; 45(5-6):279-86. PubMed ID: 12083326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV.
    Stürmer M; Staszewski S; Doerr HW
    Antivir Ther; 2007; 12(5):695-703. PubMed ID: 17713153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of insertion mutations in HIV-1 reverse transcriptase causing multiple drug resistance to nucleoside analogue reverse transcriptase inhibitors.
    Sugiura W; Matsuda M; Matsuda Z; Abumi H; Okano A; Oishi T; Moriya K; Yamamoto Y; Fukutake K; Mimaya J; Ajisawa A; Taki M; Yamada K; Nagai Y
    J Hum Virol; 1999; 2(3):146-53. PubMed ID: 10413366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thymidine-analog and multi-nucleoside resistance mutations are observed in both zidovudine-naive and zidovudine-experienced subjects with viremia after treatment with stavudine-containing regimens.
    Ross L; Henry K; Paar D; Salvato P; Shaefer M; Fisher R; Liao Q; St Clair M
    J Hum Virol; 2001; 4(4):217-22. PubMed ID: 11694850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenotypic and genotypic resistance to nucleoside reverse transcriptase inhibitors in HIV-1 clinical isolates.
    Lafeuillade A; Poggi C; Hittinger G; Chadapaud S
    HIV Med; 2001 Oct; 2(4):231-5. PubMed ID: 11737402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Broad nucleoside-analogue resistance implications for human immunodeficiency virus type 1 reverse-transcriptase mutations at codons 44 and 118.
    Romano L; Venturi G; Bloor S; Harrigan R; Larder BA; Major JC; Zazzi M
    J Infect Dis; 2002 Apr; 185(7):898-904. PubMed ID: 11920313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.